{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T13:08:50Z","timestamp":1769605730409,"version":"3.49.0"},"reference-count":35,"publisher":"Medical Journals Sweden AB","license":[{"start":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T00:00:00Z","timestamp":1656460800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Derm Venereol"],"abstract":"<jats:p>In paediatric psoriasis, few studies have evaluated methotrexate effectiveness, adverse events and folic acid regimen. Therefore this study prospectively assessed methotrexate adverse events and effectiveness in paediatric patients with psoriasis in a real-world setting. Furthermore, gastrointestinal adverse events and methotrexate effectiveness were compared between folic acid regimens (5 mg once weekly vs 1 mg 6 times weekly). Data for paediatric patients with psoriasis treated with methotrexate from September 2008 to October 2020 were extracted from Child-CAPTURE, a prospective, daily clinical practice registry. Effectiveness was determined by Psoriasis Area and Severity Index (PASI). Comparison of persistent gastrointestinal adverse events between folic acid regimens were assessed through Kaplan\u2013Meier analysis. A total of 105 paediatric patients with plaque psoriasis (41.0% male, mean age 14.1 years) were included. At week 24 and 48, an absolute PASI \u2264\u20092.0 was achieved by approximately one-third of all patients. During follow-up, 46.7% reported \u2265\u20091 persistent adverse events. After 1 and 2 years, approximately one-quarter of patients achieved a PASI \u2264\u20092.0 without persistent adverse events. Although non-significant, a possible trend towards lower occurrence of gastrointestinal adverse events was found for folic acid 1 mg 6 times weekly (p\u2009=\u20090.196), with similar effectiveness between folic acid regimens. These findings show that a subgroup of paediatric patients with psoriasis responded well to methotrexate treatment without considerable side-effects during a 2-year follow-up.<\/jats:p>","DOI":"10.2340\/actadv.v102.1000","type":"journal-article","created":{"date-parts":[[2022,5,23]],"date-time":"2022-05-23T12:54:43Z","timestamp":1653310483000},"page":"adv00745","source":"Crossref","is-referenced-by-count":7,"title":["Real-world Methotrexate Use in a Prospective Cohort of Paediatric Patients with Plaque Psoriasis: Effectiveness, Adverse Events and Folic Acid Regimen"],"prefix":"10.2340","author":[{"given":"Finola M.","family":"Bruins","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maartje R.","family":"Van Acht","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inge M.G.J.","family":"Bronckers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans M.M.","family":"Groenewoud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elke M.G.J.","family":"De Jong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marieke M.B.","family":"Seyger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1183","published-online":{"date-parts":[[2022,6,29]]},"reference":[{"key":"20002","doi-asserted-by":"crossref","unstructured":"Bronckers I, Seyger MMB, West DP, Lara-Corrales I, Tollefson M, Tom WL, et al. Safety of Systemic Agents for the Treatment of Pediatric Psoriasis. JAMA Dermatol 2017; 153: 1147-1157.","DOI":"10.1001\/jamadermatol.2017.3029"},{"key":"20003","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1001\/jamadermatol.2017.3029","DOI":"10.1001\/jamadermatol.2017.3029"},{"key":"20004","doi-asserted-by":"crossref","unstructured":"Bronckers I, Paller AS, West DP, Lara-Corrales I, Tollefson MM, Tom WL, et al. A comparison of psoriasis severity in pediatric patients treated with methotrexate vs biologic agents. JAMA Dermatol 2020; 156: 384-392.","DOI":"10.1001\/jamadermatol.2019.4835"},{"key":"20005","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1001\/jamadermatol.2019.4835","DOI":"10.1001\/jamadermatol.2019.4835"},{"key":"20006","doi-asserted-by":"crossref","unstructured":"Charbit L, Mah\u00e9 E, Phan A, Chiaverini C, Boralevi F, Bourrat E, et al. Systemic treatments in childhood psoriasis: a French multicentre study on 154 children. Br J Dermatol 2016; 174: 1118-1121.","DOI":"10.1111\/bjd.14326"},{"key":"20007","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/bjd.14326","DOI":"10.1111\/bjd.14326"},{"key":"20008","doi-asserted-by":"crossref","unstructured":"Ergun T, Seckin Gencosmanoglu D, Alpsoy E, Bulbul-Baskan E, Saricam MH, Salman A, et al. Efficacy, safety and drug survival of conventional agents in pediatric psoriasis: a multicenter, cohort study. J Dermatol 2017; 44: 630-634.","DOI":"10.1111\/1346-8138.13713"},{"key":"20009","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/1346-8138.13713","DOI":"10.1111\/1346-8138.13713"},{"key":"20010","doi-asserted-by":"crossref","unstructured":"van Geel MJ, Oostveen AM, Hoppenreijs EP, Hendriks JC, van de Kerkhof PC, de Jong EM, et al. Methotrexate in pediatric plaque-type psoriasis: long-term daily clinical practice results from the Child-CAPTURE registry. J Dermatolog Treat 2015; 26: 406-412.","DOI":"10.3109\/09546634.2014.996515"},{"key":"20011","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3109\/09546634.2014.996515","DOI":"10.3109\/09546634.2014.996515"},{"key":"20012","doi-asserted-by":"crossref","unstructured":"Papp K, Tha\u00e7i D, Marcoux D, Weibel L, Philipp S, Ghislain PD, et al. Efficacy and safety of adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: a randomised, double-blind, phase 3 trial. Lancet 2017; 390: 40-49.","DOI":"10.1016\/S0140-6736(17)31189-3"},{"key":"20013","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/S0140-6736(17)31189-3","DOI":"10.1016\/S0140-6736(17)31189-3"},{"key":"20014","doi-asserted-by":"crossref","unstructured":"van der Kraaij GE, Balak DMW, Busard CI, van Cranenburgh OD, Chung Y, Driessen RJB, et al. Highlights of the updated Dutch evidence- and consensus-based guideline on psoriasis 2017. Br J Dermatol 2019; 180: 31-42.","DOI":"10.1111\/bjd.17198"},{"key":"20015","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/bjd.17198","DOI":"10.1111\/bjd.17198"},{"key":"20016","doi-asserted-by":"crossref","unstructured":"Menter A, Cordoro KM, Davis DMR, Kroshinsky D, Paller AS, Armstrong AW, et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients. J Am Acad Dermatol 2020; 82: 161-201.","DOI":"10.1016\/j.jaad.2019.08.049"},{"key":"20017","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaad.2019.08.049","DOI":"10.1016\/j.jaad.2019.08.049"},{"key":"20018","doi-asserted-by":"crossref","unstructured":"Shea B, Swinden MV, Tanjong Ghogomu E, Ortiz Z, Katchamart W, Rader T, et al. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. Cochrane Database Syst Rev 2013; 2013: Cd000951.","DOI":"10.1002\/14651858.CD000951.pub2"},{"key":"20019","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1002\/14651858.CD000951.pub2","DOI":"10.1002\/14651858.CD000951.pub2"},{"key":"20020","doi-asserted-by":"crossref","unstructured":"Eisert L, Augustin M, Bach S, Dittmann M, Eiler R, F\u00f6lster-Holst R, et al. S2k guidelines for the treatment of psoriasis in children and adolescents - short version part 2. J Dtsch Dermatol Ges 2019; 17: 959-973.","DOI":"10.1111\/ddg.13936"},{"key":"20021","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/ddg.13936","DOI":"10.1111\/ddg.13936"},{"key":"20022","unstructured":"van den Bemt BJ, den Broeder AA, Van der Burgt M, Fransen J, van Ede AE, van den Hoogen FH. (Bi)Weekly folic acid supplementation might be inferior to a daily folic acid dosing schedule in the prevention of methotrexate-related toxicity in patients with rheumatoid arthritis. Clin Exp Rheumatol 2015; 33: 767-768."},{"key":"20023","doi-asserted-by":"crossref","unstructured":"Sasaki K, Tsuji T, Kimoto Y, Yanagihara Y, Masuguchi K, Chikamori A, et al. Usefulness of daily folic acid supplementation during methotrexate treatment of Japanese patients with rheumatoid arthritis. Mod Rheumatol 2021; 31: 108-113.","DOI":"10.1080\/14397595.2020.1743493"},{"key":"20024","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1080\/14397595.2020.1743493","DOI":"10.1080\/14397595.2020.1743493"},{"key":"20025","doi-asserted-by":"crossref","unstructured":"Eichenfield LF, Paller AS, Tom WL, Sugarman J, Hebert AA, Friedlander SF, et al. Pediatric psoriasis: evolving perspectives. Pediatr Dermatol 2018; 35: 170-181.","DOI":"10.1111\/pde.13382"},{"key":"20026","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/pde.13382","DOI":"10.1111\/pde.13382"},{"key":"20027","doi-asserted-by":"crossref","unstructured":"Gordon KB, Reich K, Crowley JJ, Korman NJ, Murphy FT, Poulin Y, et al. Disease activity and treatment efficacy using patient-level Psoriasis Area and Severity Index scores from tildrakizumab phase 3 clinical trials. J Dermatolog Treat 2022; 33: 219-228.","DOI":"10.1080\/09546634.2020.1747590"},{"key":"20028","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1080\/09546634.2020.1747590","DOI":"10.1080\/09546634.2020.1747590"},{"key":"20029","doi-asserted-by":"crossref","unstructured":"Puig L, Dossenbach M, Berggren L, Ljungberg A, Zachariae C. Absolute and relative Psoriasis Area and Severity Indices (PASI) for comparison of the efficacy of ixekizumab to etanercept and placebo in patients with moderate-to-severe plaque psoriasis: an integrated analysis of UNCOVER-2 and UNCOVER-3 outcomes. Acta Derm Venereol 2019; 99: 971-977.","DOI":"10.2340\/00015555-3245"},{"key":"20030","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2340\/00015555-3245","DOI":"10.2340\/00015555-3245"},{"key":"20031","doi-asserted-by":"crossref","unstructured":"Zweegers J, Roosenboom B, van de Kerkhof PC, van den Reek JM, Otero ME, Atalay S, et al. Frequency and predictors of a high clinical response in patients with psoriasis on biological therapy in daily practice: results from the prospective, multicenter BioCAPTURE cohort. Br J Dermatol 2017; 176: 786-793.","DOI":"10.1111\/bjd.14888"},{"key":"20032","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/bjd.14888","DOI":"10.1111\/bjd.14888"},{"key":"20033","unstructured":"services USdohah. Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 2017. [Accessed 12 december 2021] Available from: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_5x7.pdf."},{"key":"20034","doi-asserted-by":"crossref","unstructured":"Miller CJ, Smith SN, Pugatch M. Experimental and quasi-experimental designs in implementation research. Psychiatry Res 2020; 283: 112452.","DOI":"10.1016\/j.psychres.2019.06.027"},{"key":"20035","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.psychres.2019.06.027","DOI":"10.1016\/j.psychres.2019.06.027"},{"key":"20036","unstructured":"van Dijkhuizen EH, Pouw JN, Scheuern A, H\u00fcgle B, Hardt S, Ganser G, et al. Methotrexate intolerance in oral and subcutaneous administration in patients with juvenile idiopathic arthritis: a cross-sectional, observational study. Clin Exp Rheumatol 2016; 34: 148-154."}],"container-title":["Acta Dermato-Venereologica"],"original-title":[],"link":[{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/1000\/5771","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/1000\/5772","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/1000\/5771","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T12:54:49Z","timestamp":1656507289000},"score":1,"resource":{"primary":{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/view\/1000"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,29]]},"references-count":35,"URL":"https:\/\/doi.org\/10.2340\/actadv.v102.1000","relation":{},"ISSN":["1651-2057","0001-5555"],"issn-type":[{"value":"1651-2057","type":"electronic"},{"value":"0001-5555","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6,29]]}}}